

## THE DISTILLERY

## This week in therapeutics

| Targ<br>Indication path | et/marker/<br>way                                     | Summary   | Licensing status     | Publication and contact<br>information   |
|-------------------------|---|---|----------------------|--|
| Neurology               |   |   |                      |  |
| prolif<br>activa        | kisome<br>feration–<br>ated receptor-α<br>RA; PPAR-α) | Studies in rats suggest that treatment<br>with fatty acid ethanolamides could treat<br>nicotine addiction. In rats, intracerebral<br>administration of oleoylethanolamide (OEA) and<br>palmitoylethanolamide (PEA) activated PPAR- $\alpha$<br>in the brain, which inhibited the dopaminergic<br>neuronal response to nicotine compared with that<br>seen in control rats. Next steps include developing<br>stable OEA and PEA analogs that can cross the<br>blood-brain barrier.<br>There are at least 15 PPAR- $\alpha$ agonists in<br>developmental stages ranging from preclinical<br>to marketed to treat diabetes, dyslipidemia and<br>metabolic disorders. | Patented; unlicensed | Melis, M. <i>et al. J. Neurosci.</i> ; published<br>online Dec. 17, 2008;<br>doi:10.1523/JNEUROSCI.3221-<br>08.2008<br><b>Contact:</b> Marco Pistis, University of<br>Cagliari, Monserrato, Italy<br>e-mail:<br>mpistis@unica.it |

*SciBX* **2**(1); doi:10.1038/scibx.2009.22 Published online Jan. 8, 2009